In the previous papers1'2*, we reported novel and potent renal dehydropeptidase (DHP-I, EC 3.4.13.1 1, renal dipeptidase) inhibitors of microbial origin, WS1358A1 and Bl. Especially, WS1358A1 has a potent inhibitory activity comparable to that of cilastatin which is a clinically used DHP inhibitor in the antimicrobial combination imipenem/cilastatin3). To ascertain the possibility that WS1358A1 can be used as a counterpart in a combination therapy, a preliminary pharmacological evaluation in experimental animals was carried out.
In this paper, wedescribe the enzymekinetic study as well as the pharmacological evaluation of WS1358A1.
Materials and Methods
Enzyme Assay Renal DHPs from several species of animal were partially purified by the method described below for porcine renal DHPexcept that the procedures following the (NH4)2SO4 precipitation were omitted.
The effect of WS1358compoundsagainst the partially purified DHPswas measured by a method similar to that used for porcine DHP1}.Moreover, to ascertain the specificity of inhibitory activity, the effects of WS1358compoundsagainst metallo-enzymes other than DHP,such as carboxypeptidase A (CPase A) and leucine aminopeptidase (LAP) were determined. CPase A was assayed by using carbobenzoxyglycyl-L-phenylalanine as substrate. The activity was determined by observing the decline in absorbance at 224 nm. LAPwas assayed by using L-leucine-/?-nitroanilide as substrate. The activity was determined by observing the decline in absorbance at 405 nm. Inhibitory effects on the two enzymes were calculated in the samemanneras those on DHPX).
Purification of Porcine Renal DHP Purification of DHPfrom porcine kidney cortex to apparent homogeneity as judged by SDS polyacrylamide gel electrophoresis was carried out using procedures slightly different from those previously reported4~6).
The cortex was sliced from the intact kidney and homogenized in 25 mMsodium phosphate buffer (pH 8.0) at 46C in a Polytron homogenizer. The homogenate was adjusted to 20% butanol by the addition of butanol which had been chilled to -20°C. Solubilization of the enzyme was achieved by stirring the MAR. 1990 mixture at 4°C overnight. After dialysis for 24 hours against several changes of distilled water, the enzyme activity was concentrated by precipitation between 50~70% (NH4)2SO4. This partially purified enzyme was used to search for DHPinhibitors in fermentation broths. Further purification of renal DHPwas achieved by means of a HPLCand an affinity column chromatography. HPLCof the (NH4)2SO4fraction was carried out on a TSKSW3000column using a Waters model 6000 HPLCchromatograph with a Waters model 440 absorbance detector and a Hitach 200 recorder. Affinity column chromatography was performed using a procedure reported by Kropp ei al.5\ The DHPinhibitor, cilastatin, was coupled to cyanogen bromide-activated Sepharose 4B following the manufacturer's instruction. The activity of the enzyme at various stages of purification was determined by the method described below.
Enzyme Kinetic Study
The activity of DHPwas determined by measuring the rate of enzyme-catalyzed hydrolysis of the unsaturated dipeptide glycyldehydrophenylalanine (GDP) at 37°C. The fall in absorbance of a solution of 5 x 10" 5 M of the peptide in 25 mMTris-HCl buffer (pH 7.7) was measured at 275 nm. Protein concentrations were determined by the method of Bradford7*. Enzyme units are expressed as /imol of substrate hydrolyzed/minute, and specific activity is expressed as jumol of substrate hydrolyzed/minute/mg of protein under the assay conditions described above.
The rates of enzyme-catalyzed hydrolysis of GDPand imipenem in the absence or the presence of an inhibitor were measuredin a similar manner.Theenzymeconcentrations employedin the reactions were 0.1 /ig/2.0ml for GDP and 44/jg/2.0ml for imipenem.
Determination of Urinary Recovery
For each compound or combination, a group of four mice were given 1ml water orally and administrated by iv injection. Urine was collected over 0~4 hours period. Antibiotic concentration in urine samples were determined by microbiological assay using Bacillus subtilis ATCC6633 against standard solutions of imipenem prepared in 0.05 mphosphate buffer (pH 7).
Experimental Infection
Female Jcl : ICR mice, 4 weeks of age, were purchased from Shizuoka Laboratory Animal Center, Hamamatsu, Japan. Groups of five mice were intraperitoneally injected with 108 Staphylococcus aureus 47 suspended in 5%mucin solution. Combinedtherapies were subcutaneously administrated at 1 hour after the infection. Mortalities were determined after the observation for 5 days.
Materials
CPase A from bovine pancreas (Type II-DEF) and LAP from porcine kidney microsomes (Type IV-S) were purchased from Sigma Chemical Co. Carbobenzoxyglycyl-L-phenylalanine and L-leucine-/?-nitroanilide were purchased from Peptide Institute, Inc., Osaka, Japan.
Imipenem and"cilastatin were isolated from Zienam. GDP8)was synthesized by our chemists.
CNBr-activated Sepharose 4B was purchased from Pharmacia.
Results

Specific Inhibitory
Activity of WS1358 Compounds WS1358A1and Bl were found to inhibit renal DHPsfrom several species of animal as shown in Table 1 . Especially, WS1358A1 was more potent than cilastatin against all of the DHPstested. In spite of their potent inhibitory activity against DHP, WS1358A1and Bl did not inhibit CPase A and LAP at a concentration of 100 /iM. Therefore, WS1358compounds were specific inhibitors against DHP.
Purification of Porcine Renal DHP It was necessary to purify porcine renal DHPin order to examine the inhibitory mechanismof WS1358A1 against this enzyme. In our procedure of purification, the steps of acetone precipitation, extensive washing with buffer and isoelectric precipitation previously reported have been eliminated to A summary of the typical purification is shown in Table 2 . From 94g of porcine kidney cortex, 7.8 g of protein homogenatewas obtained. The complete purification from this homogenate yielded 0.6 mgof DHP which was apparently homogeneous and had a MWof about 50,000 as judged by the SDS-polyacrylamide gel electrophoresis (data not shown). The overall purification produced an enzymeapproximately 1 ,800 times more active than the starting homogenate.
Kinetic Study of WS1358A1
Before measuring the kinetic parameters for Enzymeswere assayed using synthetic peptides as substrate. Enzymeactivity was determined by measuring the decline of absorbance in the presence or the absence of an inhibitor.
Inhibition percent was calculated as described in the text. chroma tography a All fractions were assayed using 50/im GDP as substrate in 25niM Tris-HCl buffer (pH7.7). The DHP-catalyzed hydrolysis rates were measured at 37°C in 25 him Tris-HCl buffer (pH 7.7). The enzyme was mixed with an inhibitor and pre-warmed at 37°C for 1 minute before adding the substrate. Velocity is expressed as /miol/minute. Each point shows the mean of three to four determinations. MAR. 1990 Experimental conditions were the same as in Fig. 1 . The concentration tested for Ki determination of cilastatin was 0.26 fiM. The quantity of antibiotic excreted in urine within 4 hours after the administration was measured by means of a bioassay. enzyme-catalyzed hydrolysis, a linearity between the purified enzymeconcentration and enzymeactivity against GDP was established over the enzyme concentration range of 0.05 through 10^g/ml. The kinetic parameters were then determined for GDPand imipenem in the absence or the presence of inhibitor, using the standard graphical technique of Lineweaver-Burk. Typical reciprocal plots for GDPand imipenem are shown in Fig. 1 . The following kinetic parameters of the purified enzymecould be calculated for the two substrates GDP(Km=0.3 him, Vmax = 800^mol/minute/mg) and imipenem (Km = l.l mM, Vmax = 23 /xmol/minute/mg).
WS1358A1 as well as cilastatin showed a competitive inhibition and the inhibition constants for WS1358A1using GDP and imipenem as substrates are Ki, 2x lO"9, 1.6x 10~7m, respectively. The inhibition constants for WS1358A1compared with those of cilastatin are listed in Table 3 .
Effect of WS1358A1 on Urinary Recovery of Imipenem As shown in Table 4 , the mean urinary recovery percents of imipenem intraveneously administrated to mice at a dose of lmg/kg without DHPinhibitor were 44.1%. However, when WS1358A1was co-administrated at a dose of 1 mg/kg with imipenem (1 : 1), the urine recovery percents increased to 63.8%. The urinary recovery of imipenemwas also significantly augmentedat the combination ratios of WS1358A1versus the antibiotic within a range of 0.5 : 1 to 2: 1 by weight. A similar effect was observed when cilastatin was used as inhibitor in place of WS1358A1.Therefore, the effect of WS1358A1in mice on urinary recovery of imipenem resembles that of cilastatin when co-administrated with imipenem to humanvolunteers9}.
Effect of WS1358A1on Experimental Infection
Although carbapenem antibiotics show strong antimicrobial activity in vitro10), their ability to protect mice from experimental infection1 1} is somewhat weak because of their susceptibility to inactivation by renal DHP. As shown in Table 5 , imipenem showed no protective activity when it was administrated alone at the doses of 0.4~2.0mg/kg. In this case, no mice survived at day 5 after challenge. But, it showed an improved protective activity when WS1358A1was co-administrated with the antibiotic at the combination ratio of 1 : 1. Twoand five of five mice were cured at the doses of 0.4 and 2.0mg/kg, respectively. The similar result was obtained when WS1358A1 was replaced by cilastatin.
Accordingly the improved protective effect of DHPinhibitors, in experimental infection related to the augmentation of urinary recovery by the inhibitors.
Discussion
The co-administration of WS1358A1 with a carbapenem antibiotic imipenem increased the urinary recovery of the antibiotic and improved the protective effect on experimental infections. The efficacy of WS1358A1 is comparable to that of cilastatin3-9). Wecan attribute the in vivo effects of WS1358A1 to the potent inhibitory activity of the compound on DHP by which carbapenem antibiotic is inactivated. In conclusion, WS1358A1should be considered in combination therapy with carbapenem antibiotics like imipenem/cilastatin.
